Up-regulated expression of type II very low density lipoprotein receptor correlates with cancer metastasis and has a potential link to β-catenin in different cancers

Table 2 Correlation between VLDLR II expression and clinical features in 52 gastric cancer patients

Parameters	Number	VLDLR II fold	P
Age at diagnosis
≥ 60 years	26	1.34 ± 0.58	0.133
< 60 years	26	1.19 ± 0.55
Gender
Male	37	1.28 ± 0.58	0.709
Female	15	1.22 ± 0.55
Body weight
≥ 60 kg	17	1.14 ± 0.31	0.565
< 60 kg	35	1.33 ± 0.65
TC
> 5.20 mmol/L	11	1.11 ± 0.20	0.662
≤ 5.20 mmol/L	41	1.31 ± 0.62
TG
> 1.70 mmol/L	9	1.02 ± 0.23	0.204
≤ 1.70 mmol/L	43	1.32 ± 0.60
Histological grade
Well to moderately differentiated	30	1.19 ± 0.55	0.165
Poorly differentiated	22	1.37 ± 0.58
Tumor size
≥ 5 cm	25	1.40 ± 0.60	0.087
< 5 cm	27	1.14 ± 0.51
Lymph node metastasis
Negative	15	1.02 ± 0.51	0.013*
Positive	37	1.35 ± 0.56
Distant metastasis
Negative	41	1.13 ± 0.41	0.004*
Positive	11	1.78 ± 0.77
TNM stage
Stage I-II	22	1.08 ± 0.46	0.011*
Stage III-IV	30	1.40 ± 0.60

Folds (VLDLR II protein in tumor/in normal) in mean ± SD, VLDLR II measured by Western blot. TC, total cholesterol (normal range: ≤ 5.20 mmol/L); TG, triglycerides (normal range: ≤ 1.70 mmol/L). Statistical analyses were performed by Mann-Whitney test.
* P < 0.05 is considered significant

ISSN: 1471-2407